Harry Yoon

10PUBLICATIONS
74CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)ChemotherapyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Mar 25, 2026
Concordance of Circulating Tumor DNA, Primary and Metastatic Tissue DNA, and Immunohistochemistry in Gastroesophageal Carcinoma.

Fares Jamal, Oudai Sahwan, Seyi Abidoye

|Mar 11, 2026
Patient-reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma.

Lisa A Kachnic, Jennifer Moughan, Theodore S Hong

|Nov 20, 2025
Immune Checkpoint Inhibitors for Mismatch Repair-Deficient Gastroesophageal Adenocarcinoma: Outcomes and Feasibility of Nonoperative Management at Mayo Clinic.

Oudai Sahwan, Fares Jamal, Rish Pai

|Jun 25, 2025
Consensus guideline for the management of gastric cancer with synchronous peritoneal metastases.

Samuel D Butensky, Varun V Bansal, David G Su

|Mar 13, 2025
First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306.

Jianming Xu, Ken Kato, Richard Hubner

|Oct 13, 2022
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study.

Andrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams

Pageof 2

Frequent Collaborators

3 joint publications

Robert R McWilliams

2 joint publications

Daniel H Ahn

2 joint publications

Mitesh Borad

2 joint publications

Haidong Dong